CLRB - התחייבויות לטווח ארוך להון Cellectar Biosciences

The debt-to-equity ratio for Cellectar Biosciences (CLRB) shows a metric value of 0.05. Exclusive patents for the PDC platform and influence within the US oncology sphere provide Cellectar Biosciences with a competitive advantage. The nature of the business requires ultra-fast radiation logistics due to the short half-life of isotopes. Meanwhile, financial results are constrained by commercialization costs and the current anticipation of an FDA verdict.

This indicator measures the proportion of long-term liabilities relative to equity, determining financial stability during revenue stress. The ratio is calculated as the relationship between loans with a maturity of more than one year and equity. By analyzing the long-term debt-to-equity ratio, an investor assesses the risk of insolvency. For Cellectar Biosciences (CLRB), the balance of borrowings is critical when financing radiopharmaceutical developments. Optimizing this ratio supports the synergy of strategic alliances in the creation of oncology therapies.